10X Genomics, Inc. (TXG)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$71.55+2.58%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge 10X Genomics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	171.35M
EPS	—	-0.23
FY 2026 · Annual
Revenue	$610M–$630M	620.84M
EPS	—	-0.746
FY 2027 · Annual
Revenue	—	681.78M
EPS	—	-0.72

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve gross profit margins above Q1 2026 level	The company focuses on improving gross profit, which was $106.2M in Q1.	Improving	gross profit falls below $100M in any quarter	Gross profit: $112.497M FY2026-Q2; GAAP. Published target: >$106.2M gross profit. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026112,497,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0bf1cdf6-76d8-4312-ae5c-ce93e53d2b63. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Gross margin increased from 70% in 2026-Q1 to 74% in 2026-Q2, improving over 72% in 2025-Q2, driven by lower manufacturing costs and tariff refunds. Management is delivering progress on margin improvement. Delivery assessment Oct 24, 2026
Maintain management confidence and execution	A supporting condition in 10X Genomics, Inc.'s published investment case. The stated target is No significant insider selling.	Improving	CEO or CFO sells large share blocks repeatedly	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve and sustain positive cash flow from operations	It targets positive cash flow from operations, with $26.1M achieved in Q1.	Improving	operating cash flow turns negative for two consecutive quarters	Cash from operations: $16.974M FY2026-Q2; GAAP. Published target: >0 USD. Target period is not explicitly aligned with this observation. Source published Aug 7, 202616,974,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Cash from operating activities declined from $40.78M in 2025-Q4 to $16.97M in 2026-Q2, indicating limited progress toward improving cash flow despite management focus. The trajectory is mixed with recent quarters showing declining cash flow. Delivery assessment Oct 24, 2026
Maintain 2026 revenue near $612.5M	A primary condition in 10X Genomics, Inc.'s published investment case. The stated target is ~$612.5M.	Intact	revenue falls below $600M in FY26	Revenue: $151.036M FY2026-Q2; GAAP. Published target: ~$612.5M. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026151,036,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0bf1cdf6-76d8-4312-ae5c-ce93e53d2b63. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.72

Unavailable → $-0.72 · observed estimates

FY2027 revenue$0.68B

$0.67B → $0.68B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$671,472,390	3 / 15
2026-07-25	Unavailable	$671,472,950	3 / 15
2026-07-26	$-0.71	$668,230,646	8 / 12
2026-07-27	Unavailable	$671,472,950	3 / 15
2026-07-28	Unavailable	$671,472,950	3 / 15
2026-07-29	$-0.71	$668,230,646	8 / 12
2026-07-30	Unavailable	$671,472,950	3 / 15
2026-07-31	$-0.71	$668,230,646	8 / 12
2026-08-01	$-0.71	$668,230,646	8 / 12
2026-08-02	Unavailable	$671,472,950	3 / 15
2026-08-03	Unavailable	$671,472,950	3 / 15
2026-08-04	$-0.71	$668,230,646	8 / 12
2026-08-05	$-0.71	$668,230,646	8 / 12
2026-08-06	$-0.71	$668,230,646	8 / 12
2026-08-08	$-0.71	$668,230,646	8 / 12
2026-08-09	Unavailable	$675,342,220	2 / 15
2026-08-10	Unavailable	$675,342,220	2 / 15
2026-08-12	$-0.71	$668,230,646	8 / 12
2026-08-13	$-0.71	$668,230,646	8 / 12
2026-08-14	$-0.71	$668,230,646	8 / 12
2026-08-15	$-0.71	$668,230,646	8 / 12
2026-08-16	$-0.71	$668,230,646	8 / 12
2026-08-17	$-0.71	$668,230,646	8 / 12
2026-08-18	$-0.71	$668,230,646	8 / 12
2026-08-19	$-0.71	$668,230,646	8 / 12
2026-08-20	$-0.72	$677,391,095	8 / 12
2026-08-21	$-0.72	$677,391,095	8 / 12
2026-08-22	$-0.72	$677,391,095	8 / 12
2026-08-23	$-0.72	$677,391,095	8 / 12
2026-08-24	$-0.72	$677,391,095	8 / 12
2026-08-25	$-0.72	$677,391,095	8 / 12
2026-08-26	$-0.72	$677,391,095	8 / 12
2026-08-27	$-0.72	$677,391,095	8 / 12
2026-08-28	$-0.72	$677,391,095	8 / 12
2026-08-29	$-0.72	$677,391,095	8 / 12
2026-08-30	$-0.72	$677,391,095	8 / 12
2026-08-31	$-0.72	$677,391,095	8 / 12
2026-09-01	$-0.72	$677,391,095	8 / 12
2026-09-02	$-0.72	$678,196,755	8 / 12
2026-09-03	$-0.72	$678,196,755	8 / 13
2026-09-04	$-0.72	$678,196,755	8 / 13
2026-09-05	$-0.72	$678,196,755	8 / 13
2026-09-06	$-0.72	$678,196,755	8 / 13
2026-09-07	$-0.72	$678,196,755	8 / 13
2026-09-08	$-0.72	$678,196,755	8 / 13
2026-09-09	$-0.72	$678,196,755	8 / 13
2026-09-10	$-0.71	$678,422,702	8 / 13
2026-09-11	$-0.71	$678,422,702	8 / 13
2026-09-12	$-0.71	$678,422,702	8 / 13
2026-09-13	$-0.71	$678,422,702	8 / 13
2026-09-14	$-0.71	$678,422,702	8 / 13
2026-09-15	$-0.71	$678,422,702	8 / 13
2026-09-16	$-0.71	$678,422,702	8 / 13
2026-09-17	$-0.71	$678,422,702	8 / 13
2026-09-18	$-0.71	$678,422,702	8 / 13
2026-09-19	$-0.71	$678,422,702	8 / 13
2026-09-20	$-0.71	$678,422,702	8 / 13
2026-09-21	$-0.71	$678,422,702	8 / 13
2026-09-22	$-0.73	$678,716,452	8 / 13
2026-09-23	$-0.73	$678,716,452	8 / 13
2026-09-24	$-0.73	$678,716,452	8 / 13
2026-09-25	$-0.73	$678,716,452	8 / 13
2026-09-26	$-0.73	$678,716,452	8 / 13
2026-09-27	$-0.73	$678,716,452	8 / 13
2026-09-28	$-0.73	$678,716,452	8 / 13
2026-09-29	$-0.73	$678,716,452	8 / 13
2026-09-30	$-0.73	$678,716,452	8 / 13
2026-10-01	$-0.73	$678,716,452	9 / 14
2026-10-02	$-0.72	$679,335,202	9 / 14
2026-10-03	$-0.72	$679,335,202	9 / 14
2026-10-04	$-0.72	$679,335,202	9 / 14
2026-10-05	$-0.72	$679,335,202	9 / 14
2026-10-06	$-0.72	$679,335,202	9 / 14
2026-10-07	$-0.72	$679,335,202	9 / 14
2026-10-08	$-0.72	$679,294,039	9 / 14
2026-10-09	$-0.72	$679,294,039	9 / 14
2026-10-10	$-0.72	$679,294,039	9 / 14
2026-10-11	$-0.72	$679,294,039	9 / 14
2026-10-12	$-0.72	$679,294,039	9 / 14
2026-10-13	$-0.72	$679,579,202	9 / 14
2026-10-14	$-0.71	$681,554,202	9 / 14
2026-10-15	$-0.70	$682,100,201	9 / 14
2026-10-16	$-0.70	$682,110,088	9 / 14
2026-10-17	$-0.70	$682,110,088	9 / 14
2026-10-18	$-0.70	$682,110,088	9 / 14
2026-10-19	$-0.70	$682,110,088	9 / 14
2026-10-20	$-0.70	$682,091,338	9 / 14
2026-10-21	$-0.70	$682,091,338	9 / 14
2026-10-22	$-0.70	$682,091,338	9 / 14
2026-10-23	$-0.72	$681,564,631	9 / 13
2026-10-24	$-0.72	$681,779,597	8 / 13

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	10
2026-06-01	6	10
2026-07-01	6	10
2026-08-01	6	10
2026-09-01	7	12
2026-10-01	7	12

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 12 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades6 maintains

Recent actions · Sep 25–Oct 24 · 6 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Stifel NicolausOct 13 · prior Aug 7

$50.00 → $70.00+40.0%

Morgan StanleyOct 12 · prior Aug 7

$40.00 → $70.00+75.0%

Canaccord GenuityOct 12 · prior Aug 10

$60.00 → $100.00+66.7%

BarclaysOct 7 · prior Jun 24

$40.00 → $110.00+175.0%

Leerink PartnersSep 29 · prior Jul 17

$40.00 → $90.00+125.0%

Piper SandlerSep 28 · prior Aug 10

$47.00 → $80.00+70.2%

Argus ResearchSep 28

$110.00New observation · no comparable prior

$0$60.50$121.00

6 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve gross profit margins above Q1 2026 levelGross profit: $112.497M
Maintain management confidence and executionDirect metric needs a verified mapping
Achieve and sustain positive cash flow from operationsCash from operations: $16.974M
Maintain 2026 revenue near $612.5MRevenue: $151.036M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-28.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

10X Genomics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a higher-risk growth business with some optionality, meaning its future prospects depend on execution that is not yet established. The multi-year view is intact, supported by recent earnings beats and steady revenue, but profitability remains unproven.

What's priced into 10X Genomics, Inc.

TXG is expensive versus peers, and the valuation reflects meaningful expectations for future progress. The evidence labels those expectations as unjustified, though confidence in that assessment is low; valuation fragility is rated low because the concern is expense alone, not a combination of weak fundamentals and turbulence.

What the fundamentals likely do

Near term, revenue is steady and management raised 2026 guidance to reflect 2%-5% growth over 2025 excluding non-recurring items. Gross margin improved, but cash from operations declined from late 2025 to 2026-Q2, and the business remains loss-making. Elevated risk and a high-miss-rate industry make execution less certain despite recent earnings beats.

What 10X Genomics, Inc. hinges on

The multi-year thesis depends on management sustaining revenue guidance, improving margins, and making progress toward positive operating cash flow. A reversal of the recent guidance increase would damage credibility, while continued weakness in jobs data could pressure cyclical Healthcare names; strong results and higher guidance from sector bellwethers could support sector momentum.